My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
September 2014
Policy and Advocacy
Advocacy on New Antibacterial Drug Pathway Continues in the House

A bipartisan group of 37 members of the House of Representatives have co-sponsored the Antibiotic Development to Advance Patient Treatment (ADAPT) Act, H.R. 3742, which has been promoted by IDSA. The ADAPT Act would permit a new antibiotic’s safety and effectiveness to be studied in smaller, more rapid clinical trials. In return, the drug would be narrowly indicated for use in a limited population of patients. ADAPT includes provisions to help guide the appropriate use of these drugs including:  requiring the label to state the drug’s limited indication, granting the Food and Drug Administration authority to pre-review the drug’s promotional materials, and directing the Centers for Disease Control and Prevention (CDC) to monitor the drug’s use. IDSA is also advocating for the inclusion of a visual element on the drug’s label to clearly mark the drug as different from traditional antibiotics.

IDSA is urging additional members of the House to cosponsor the legislation so that it might be advanced this fall. IDSA members can support this effort in just a few minutes by emailing their representative through the IDSA Action Center today.




< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
Sanford Guide Releases Mobile App for Lab Diagnosis of Infectious Diseases
NVAC Standards for Adult Immunization: What Do They Mean for the ID Specialist?
HCV Treatment Guidance Now Includes Information on Prioritizing Patients
Clinical Practice Management
New Resources on Co-management Agreements and Antimicrobial Stewardship Now Available
IDSA, HIVMA Appeal Medicaid Restrictions on Who Treats HCV
Policy and Advocacy
IDSA Convenes New National Stakeholder Group on Antimicrobial Resistance
Federal Funding Process Stalled Just Weeks Ahead of New Fiscal Year
Health Groups Share Federal Funding Experiences with Congress
Advocacy on New Antibacterial Drug Pathway Continues in the House
IDSA Submits Comments to FDA on Draft Guidance on Diagnostics
Global ID
Highlights from 20th International AIDS Conference
Education and Resources
Concerns Regarding Changes to MOC Requirements Shared with ABIM
IDSA Education and Research Foundation Launches New Website
Sign Up for OFID Table of Contents Alerts
You and Your Colleagues
In Memoriam: Gene H. Stollerman, MD, FIDSA (1920-2014)
IDSA Announces 2014 Fellows
Members on the Move
New Members
Top Stories
Presidentís Message: With the Spotlight on Drug Resistance, Itís Time for the ID Specialistís Role in Stewardship to Shine
IDSA Provides Ebola Resources for ID Clinicians
Countdown to IDWeek 2014
IDSA Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.